128 related articles for article (PubMed ID: 11699396)
1. Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients.
Chen CL; Rawwas J; Sorrell A; Eddy L; Uckun FM
Leuk Lymphoma; 2001 Jul; 42(3):317-27. PubMed ID: 11699396
[TBL] [Abstract][Full Text] [Related]
2. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia.
Edick MJ; Gajjar A; Mahmoud HH; van de Poll ME; Harrison PL; Panetta JC; Rivera GK; Ribeiro RC; Sandlund JT; Boyett JM; Pui CH; Relling MV
J Clin Oncol; 2003 Apr; 21(7):1340-6. PubMed ID: 12663724
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of total and unbound etoposide.
Nguyen L; Chatelut E; Chevreau C; Tranchand B; Lochon I; Bachaud JM; Pujol A; Houin G; Bugat R; Canal P
Cancer Chemother Pharmacol; 1998; 41(2):125-32. PubMed ID: 9443625
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic optimisation of treatment with oral etoposide.
Toffoli G; Corona G; Basso B; Boiocchi M
Clin Pharmacokinet; 2004; 43(7):441-66. PubMed ID: 15139794
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic approach to compare oral and i.v. administration of etoposide.
Würthwein G; Krümpelmann S; Tillmann B; Real E; Schulze-Westhoff P; Jürgens H; Boos J
Anticancer Drugs; 1999 Oct; 10(9):807-14. PubMed ID: 10587290
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas.
Kroschinsky FP; Friedrichsen K; Mueller J; Pursche S; Haenel M; Prondzinsky R; Ehninger G; Schleyer E
Cancer Chemother Pharmacol; 2008 Apr; 61(5):785-90. PubMed ID: 17579865
[TBL] [Abstract][Full Text] [Related]
8. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation.
Lowis SP; Pearson AD; Newell DR; Cole M
Cancer Res; 1993 Oct; 53(20):4881-9. PubMed ID: 8402676
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacokinetic aspects of oral administration of etoposide].
Tillmann B; Krümpelmann S; Würthwein G; Wagner A; Schulze-Westhoff P; Hempel G; Jürgens H; Boos J
Klin Padiatr; 1998; 210(4):159-64. PubMed ID: 9743946
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents.
Kato Y; Nishimura S; Sakura N; Ueda K
Pediatr Int; 2003 Feb; 45(1):74-9. PubMed ID: 12654074
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia.
Kearns CM; Blakley RL; Santana VM; Crom WR
Cancer Res; 1994 Mar; 54(5):1235-9. PubMed ID: 7906999
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability of etoposide after oral administration of the solution marketed for intravenous use: therapeutic and pharmacoeconomic perspectives.
Aguilar Ponce JL; Flores-Picazo Y; Pérez-Urizar J; Castañeda-Hernández G; Zinser-Sierra JW; Dueñas-González A; Calderón-Flores E; Segura-Pacheco BA; de la Garza-Salazar J
Arch Med Res; 1999; 30(3):212-5. PubMed ID: 10427872
[TBL] [Abstract][Full Text] [Related]
13. The effect of atovaquone on etoposide pharmacokinetics in children with acute lymphoblastic leukemia.
van de Poll ME; Relling MV; Schuetz EG; Harrison PL; Hughes W; Flynn PM
Cancer Chemother Pharmacol; 2001 Jun; 47(6):467-72. PubMed ID: 11459198
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer.
Millward MJ; Newell DR; Yuen K; Matthews JP; Balmanno K; Charlton CJ; Gumbrell L; Lind MJ; Chapman F; Proctor M
Cancer Chemother Pharmacol; 1995; 37(1-2):161-7. PubMed ID: 7497587
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.
Aita P; Robieux I; Sorio R; Tumolo S; Corona G; Cannizzaro R; Colussi AM; Boiocchi M; Toffoli G
Cancer Chemother Pharmacol; 1999; 43(4):287-94. PubMed ID: 10071979
[TBL] [Abstract][Full Text] [Related]
16. Bioavailability of low-dose oral etoposide.
Hande KR; Krozely MG; Greco FA; Hainsworth JD; Johnson DH
J Clin Oncol; 1993 Feb; 11(2):374-7. PubMed ID: 8426216
[TBL] [Abstract][Full Text] [Related]
17. Effect of grapefruit juice intake on etoposide bioavailability.
Reif S; Nicolson MC; Bisset D; Reid M; Kloft C; Jaehde U; McLeod HL
Eur J Clin Pharmacol; 2002 Oct; 58(7):491-4. PubMed ID: 12389073
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
[TBL] [Abstract][Full Text] [Related]
19. Plasma etoposide catechol increases in pediatric patients undergoing multiple-day chemotherapy with etoposide.
Zheng N; Felix CA; Pang S; Boston R; Moate P; Scavuzzo J; Blair IA
Clin Cancer Res; 2004 May; 10(9):2977-85. PubMed ID: 15131033
[TBL] [Abstract][Full Text] [Related]
20. Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia.
Relling MV; Mahmoud HH; Pui CH; Sandlund JT; Rivera GK; Ribeiro RC; Crist WM; Evans WE
J Clin Oncol; 1996 Feb; 14(2):399-404. PubMed ID: 8636749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]